Background: Pendrin is a multifunctional anion transporter that exchanges chloride and iodide in the thyroid, as well as chloride and bicarbonate in the inner ear, kidney and airways. Loss or reduction in the function of pendrin results in both syndromic (Pendred syndrome) and non-syndromic (nonsyndromic enlarged vestibular aqueduct (ns-EVA)) hearing loss. Factors inducing an up-regulation of pendrin in the kidney and the lung may have an impact on the pathogenesis of hypertension, chronic obstructive pulmonary disease (COPD) and asthma. Here we characterize the ion transport activity of wildtype (WT) pendrin and seven of its allelic variants selected among those reported in the single nucleotide polymorphisms data base (dbSNPs), some of which were previously identified in a cohort of individuals with normal hearing or deaf patients belonging to the Spanish population. Methods: WT and mutated pendrin allelic variants were functionally characterized in a heterologous over-expression The transport activity of pendrin P70L, P301L and F667C is completely abolished; pendrin V609G and D687Y allelic variants are functionally impaired but retain significant transport. Pendrin F354S activity is indistinguishable from WT, while pendrin V88I and G740S exhibit a gain of function. Conclusion: Amino acid substitutions involving a proline always result in a severe loss of function of pendrin. Two hyperfunctional allelic variants (V88I, G740S) have been identified, and they may have a contributing role in the pathogenesis of hypertension, COPD and asthma.
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Introduction
Pendrin (PDS, SLC26A4) is a multifunctional anion exchanger [1, 2] expressed in tissues as diverse as the thyroid gland, inner ear, kidney, and airways. Pendrin plays different roles in these various tissues and human 468 pathological conditions are well established (Pendred syndrome, enlarged vestibular aqueduct (EVA)) or hypothesized (hypertension, chronic obstructive pulmonary disease (COPD), asthma) to be associated with loss of function of pendrin or its upregulation, respectively.
Pendrin malfunction mainly affects the thyroid gland and the inner ear. In the thyroid gland, pendrin is expressed on the apical membrane of thyrocytes [3] and most likely exchanges iodide for chloride [4, 5] , thereby mediating iodide flux into the follicular lumen [6] . In the inner ear, pendrin is expressed in the endolymphatic sac and duct, saccule, utricle, ampulla and cochlea [7] and is responsible for bicarbonate secretion into the endolymph [8, 9] , thereby controlling and conditioning its pH and ion composition. Pendrin reduction or loss of function causes both syndromic (Pendred syndrome) and non syndromic hearing loss. Pendred syndrome (OMIM#274600) [10] is an autosomal recessive disease characterized by the association of sensorineural hearing loss and a partial iodide organification defect, clinically revealed by a positive perchlorate discharge test, with or without goiter and hypothyroidism [11, 12] . Deafness is due to malformations of the inner ear, typically an EVA or a dysplastic (Mondini) cochlea [13] , as well as alterations of the endocochlear potential [8] . Moreover, monoallelic [14] [15] [16] or biallelic [16] mutations of the pendrin gene can result in non-syndromic enlarged vestibular aqueduct (ns-EVA) without an obvious thyroid phenotype.
The pathological conditions potentially linked to hyperfunction and/or overexpression of pendrin are related to the role of the transporter in the kidney and airways. In the kidney, pendrin is expressed on the apical membrane of β and non-α, non-β intercalated cells within the cortical collecting duct of the nephron [17, 18] and mediates bicarbonate secretion [17, 19] via exchange of bicarbonate for chloride [1] . Recently it has been proposed that pendrin could contribute to the pathogenesis of hypertension [20] . Indeed, pendrin expression and activity are upregulated by aldosterone analogues [21] and angiotensin II [22] and, interestingly, pendrin knock-out mice are protected against hypertension induced by aldosterone analogues [21, 23] . As a consequence, it has been suggested that pendrin-mediated chloride transport through intercalated cells might represent a potential target for blood pressure control [24] . In the airways, an increase in pendrin mRNA expression has been described in murine asthma models [25] and has been associated with mucus overproduction in murine models of bronchial asthma and COPD [26] . Moreover, chloride reabsorption via pendrin could participate in the control of airway surface liquid thickness [27] . An excess of chloride reabsorption could be paralleled by water reabsorption, leading to the production of a compact layer of dehydrated mucus, with a possible role in exacerbations of asthma and COPD. This phenomenon is particularly important during inflammation, when pro-inflammatory cytokines lead to increases in pendrin expression [25] [26] [27] [28] [29] [30] . These findings collectively suggest that pendrin may be a therapeutic target candidate for bronchial asthma and COPD.
Functional tests of mutated pendrin allelic variants found in patients with Pendred syndrome or ns-EVA revealed that the pathology is linked to a reduction or a loss of function in pendrin activity [31] . More than 170 mutations within the pendrin gene have been identified so far (http://www.healthcare.uiowa.edu/labs/ pendredandbor/slcMutations.htm), but the functional characterization for only a minority of them is available (for more detailed information regarding the functional characterization of pendrin and its allelic variants, see [32] ). Besides clinical and radiological assessments, sequencing of the pendrin gene is essential for a definitive diagnosis of Pendred syndrome and ns-EVA [13] . In addition, in cases where mutations within the pendrin coding region are detected, the diagnosis could be corroborated by a functional test of the respective allelic variant. Indeed, the clinical condition of pseudo-Pendred syndromes [33] [34] [35] [36] and the high incidence of benign functional pendrin polymorphisms in some populations [37] could lead to an incorrect definition of the genetic cause of the disease. Single nucleotide pendrin polymorphisms are continuously detected and reported in the single nucleotide polymorphisms database (dbSNPs) of the National Center for Biotechnology Information. Some of them (Table 1) have also been found in a group of normalhearing Spanish controls (F354S, F667C), as well as in a cohort of deaf Spanish patients and controls (V609G, G740S) [37] .
Here we set out to determine the function of seven selected allelic variants of pendrin (P70L, P301L, F354S, V609G, F667C, D687Y, G740S, Table 1 ), all of which are reported in the dbSNPs, with the aim to (i) discriminate between benign polymorphisms and potentially pathological mutations, (ii) identify amino acids substitutions with functional impact and (iii) compare and validate results obtained with two different methods (fluorometric and radiometric) for evaluating the iodide transport ability of pendrin. In addition, the transport activity of the previously characterized pendrin allelic variant V88I [37] was further explored.
Materials and Methods

Cloning procedures and plasmid constructs
Standard procedures were used for DNA preparation, cloning, purification, and sequencing. The pTARGET (Promega Corporation) vector, containing the open reading frame (ORF) of full length human pendrin cloned from normal thyroid tissue, was originally provided by Prof. P. Beck-Peccoz, University of Milan (Italy). The pendrin mutants were made using the QuikChange The plasmid encoding for the enhanced yellow fluorescent protein H148Q/I152L (an EYFP mutant with substantially improved sensitivity for iodide [38] and hereafter referred to as EYFP*) was obtained by site-directed mutagenesis of the pEYFPN1 vector (Clontech) with the following primers: forward: 5'GGA GTA CAA CTA CAA CAG CCA GAA CGT CTA TTT GAT GGC CGA CAA GCA GAA G3' and reverse: 5'CTT CTG CTT GTC GGC CAT CAA ATA GAC GTT CTG GCT GTT GTA GTT GTA CTC C3'. All plasmid inserts were sequenced prior to use in experiments (Microsynth AG, Switzerland).
Cell culture and transient transfection
Human embryonic kidney (HEK) 293 Phoenix cells [39] were cultured in Minimum Essential Eagle Medium (MEM, Sigma, Austria) supplemented with 10% fetal bovine serum (FBS, Cambrex Bio Science), 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 1 mM pyruvic acid (sodium salt). TSA-201 cells, a transformed subclone of human embryonic kidney cell line 293, stably expressing simian virus 40 T-antigen, were cultured in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin.
The cells were maintained at 37°C, 5% CO 2 , 95% air and 100% humidity. Subcultures were routinely established every second to third day by seeding the cells into 100 mm diameter Petri dishes following trypsin/EDTA treatment. For functional tests (fluorometric methods), HEK 293 Phoenix cells were seeded into poly-L-lysine-coated 96-multiwells, grown overnight and transfected with a total amount of 0.2 µg/well of plasmid DNA by the calcium phosphate co-precipitation method [37] . Functional tests were performed 52 hours posttransfection.
Fluorometric method (iodide influx)
For measuring iodide influx, cells were co-transfected with 0.1 µg of pEYFP*N1 plasmid and 0.1 µg of pTARGET plasmid bearing the cDNA of wild-type (WT) or mutated pendrin. Control cells were co-transfected with pEYFP*N1 and the empty pTARGET vectors. The functional test was performed as already described [37, [40] [41] [42] [43] , with adaptations allowing the use of a multiplate reader. Shortly, cells were washed from the culture medium and bathed in 70 µls of "high chloride" solution (in mM: KCl 2, NaCl 135, CaCl 2 In our conditions, the calculated pKa for BCECF-AM was 7.04. Results were expressed as fluorescence ratio (λ 490 /λ 450 ) variations (ΔRatio%).
Radiolabeled iodide uptake studies (iodide efflux)
For radiolabeled iodide uptake assays, a pCMX plasmid containing Na + /I -symporter (NIS) cDNA (500 ng/well), and pTARGET plasmids carrying WT pendrin cDNA or pendrin mutants (500 ng/well) were transfected using the calcium phosphate co-precipitation method. The empty pCMX and pTARGET vectors were used as negative controls. In cotransfection experiments of NIS and pendrin constructs, the total amount of DNA was kept constant by supplementation with empty vector. Radiolabeled iodide efflux studies were performed 48 hours following transfection of TSA-201 cells grown to 80% confluency in 12-well tissue culture plates. Cells were washed once with 1x PBS and incubated with HBSS containing 10 mM HEPES (pH 7.4), 1 mM methimazole, 1 mM DTT, and 10 -5 M cold NaI labeled with Na 125 I (20 mCi/mmol) for 30 min at 37°C. The radiolabeled iodide solution was aspirated and cells were permeabilized using 1% Triton-X in 1x PBS. The intracellular iodide content was determined by quantifying the amount of radiolabeled iodide in the cell lysates using a gamma counter.
Salts, chemicals and drugs
All salts and chemicals used were of "pro analysis" grade.
Statistical Analysis
All data are expressed as arithmetic means ± S.E.M. For statistical analysis, GraphPad Prism software (version 4.00 for Windows, GraphPad Software, San Diego, California, USA) was used. Significant differences between means were tested by Student's t test or one way Analysis of Variance (ANOVA) with Dunnet's post-test, as appropriate. Statistically significant differences were assumed at p<0.05 (* p<0.05; **p<0.01); (n) corresponds to the number of independent measurements.
Results
Iodide influx
In order to test the iodide influx of WT pendrin and its allelic variants (Table 1) , we measured the EYFP* fluorescence in cells over-expressing WT or mutated pendrin before and after addition of iodide to the Table 1 . Pendrin allelic variants characterized in the present study. a data are taken from [37] ; n, number of alleles tested; the numbers indicate how often the mutant allele was identified in the group of normalhearing controls or deaf patients. CT = computed tomography. [2, 4, 41] , the presence of extracellular iodide should induce an iodide flux into the cytoplasm. Iodide is a much better quencher of EYFP* fluorescence than chloride, therefore, an increase in intracellular iodide should lead to a decrease of EYFP* fluorescence [38] . Indeed, as shown in Fig. 1a , addition of iodide to the extracellular solution led to a marked decrease (ΔF% = -61.3 ± 3.5%, n = 18) of EYFP* fluorescence in cells expressing WT pendrin. This value is significantly different from that measured in cells overexpressing only EYFP* (control) i.e. 22.2 ± 3.2%, n = 18, p<0.01. These results confirm that pendrin is an iodide transporter [44, 45] most likely acting as a Cl -/I -anion exchanger in this system [41] .
The addition of iodide to the extracellular solution led to only a small change in the intracellular fluorescence of cells over-expressing the mutated pendrin isoforms P70L, P301L and F667C (ΔF% for P70L: 3.2 ± 2.9%, n = 48; for P301L: -1.8 ± 3.8%, n = 18; for F667C: 3.8 ± 8.9%, n = 18). These values were significantly reduced compared to WT (p<0.01) and not significantly different from control, indicating that the corresponding mutants display a loss of function. In contrast, the changes Cell Physiol Biochem 2011; 28:467-476 in intracellular fluorescence of cells over-expressing pendrin V609G (ΔF% = -23.9 ± 9.0, n = 18) and D687Y (ΔF% = -17.5 ± 10.6, n = 16) were significantly different from both the WT and control (p<0.01), indicating that these mutants retain residual transport activity, even if reduced with respect to the WT. The transport activity of pendrin F354S (ΔF% = -54.5 ± 5.3, n = 17) was indistinguishable from WT. Surprisingly, the iodide influx mediated by pendrin G740S (ΔF% = -81.2 ± 7.2, n = 18) was significantly higher (~32%) compared to WT (p<0.05).
Iodide efflux
In order to analyze the ability of pendrin allelic variants to mediate iodide efflux, we co-transfected non-polarized TSA-201 cells, lacking endogenous pendrin expression, with the sodium iodide transporter NIS to allow cells to accumulate iodide. TSA-201 cells transiently expressing NIS alone demonstrate a significant increase (488%) in iodide uptake, compared with cells transfected with the empty vector (control, Fig. 1b) . Co-expression of NIS and WT pendrin (intracellular content of iodide in cpm/well: 6162 ± 163, n = 3, Fig. 1b) led to a significant decrease (~64%) in intracellular iodide concentration compared with cells transfected only with NIS (17334 ± 26 cpm/well, n = 3, p<0.01), thereby confirming that pendrin can mediate iodide efflux in this system [45, 46] . Co-transfection of cells with NIS and the previously characterized pendrin loss-of-function mutant L676Q, found in a patient with Pendred syndrome [45] , did not result in a significant decrease in intracellular iodide (16863 ± 153 cpm/well, n= 3), and served as a negative control. Cells co-expressing pendrin V88I and NIS, as well as those co-transfected with pendrin G740S and NIS, showed a slightly larger decrease (68% and 69% respectively) in intracellular iodide amount (in cpm/well: 5572 ± 70, n = 3 and 5364 ± 69, n= 3 respectively, Fig. 1b ) than cells co-transfected with WT pendrin and NIS. These findings suggest that the pendrin allelic variants V88I and G740S may have a minor, but significant (p<0.05 and p<0.01 respectively), gain of function. Co-transfection of pendrin F354S and NIS led to a 66% decrease in intracellular iodide content (4352 ± 143, n = 3, Fig. 1b) , not statistically different from the decrease obtained following transfection with WT pendrin and NIS, indicating that this mutation does not affect the ability of the protein to mediate iodide transport. The intracellular iodide concentration of cells co-expressing pendrin V609G and NIS (7275 ± 162, n = 3, Fig. 1b ) was significantly reduced with respect to cells co-expressing NIS alone (p<0.01); nevertheless, the cells co-expressing pendrin V609G and NIS showed a smaller decrease in intracellular iodide concentration if compared to cells co-expressing WT pendrin and NIS (58% vs. 64% respectively, p<0.01). These results show that the transport ability of pendrin V609G is reduced, but not completely annihilated. 
Discussion
Mutations within the coding region that reduce or annihilate pendrin transport activity are the most common cause of syndromic deafness [47] and, in addition, are found in up to 4% of patients with non-syndromic hearing loss [16] . Moreover, the upregulation of pendrin activity and/or expression by proinflammatory cytokines [25] [26] [27] [28] [29] [30] or pharmacological treatments [21, 22] may be involved in the pathogenesis of hypertension and contribute to exacerbations of asthma and COPD.
Here we determined the function of seven selected allelic variants of pendrin (P70L, P301L, F354S, V609G, F667C, D687Y, G740S, Table 1 ), all of which are reported in the dbSNPs and some of which were previously identified in a cohort of deaf Spanish patients and/or normal-hearing controls. In addition, the transport activity of the previously characterized pendrin allelic variant V88I was further explored [37] .
The allelic variants P70L, P301L and D687Y are reported in the dbSNPs, but their functional and clinical significance was unknown. The fluorometric functional test (Fig. 1a) showed that iodide transport (I -/Cl -exchange) of D687Y is significantly reduced compared to WT, but not completely blunted; in contrast, P70L and P301L displayed a complete loss of function. We conclude that P70L, P301L and D687Y could all be pathogenic. In addition, we confirmed that amino acid substitutions involving a proline always have a negative impact on pendrin function [37, 40] .
The allelic variants F354S and F667C were detected in a group of normal-hearing controls belonging to the Spanish population, but not in a cohort of deaf patients (Table 1 and [37] ); both of them are also reported in the dbSNPs. The allelic variant F354S was previously identified in compound heterozygosity in a patient with Pendred syndrome [48] and in heterozygosity with the WT allele in a patient with ns-EVA [16] and exhibited a moderate reduction in Cl -/HCO 3 -exchange activity [49] . Nevertheless, the functional characterization of pendrin F354S by the fluorometric method (Fig. 1a) , corroborated by the radiometric method (Fig. 1b) , demonstrate that its iodide transport activity is indistinguishable from the WT. In addition, the Cl -/OH -exchange activity of this variant was not affected (Fig. 2b ). These observations, along with the high incidence of this mutation in the control population (Table 1 and [37] ), indicate that F354S should be considered as a benign polymorphism and, if identified in patients with goiter and deafness, other genetic causes should be considered as determinants of the clinical phenotype. Pendrin F667C was previously identified in a family with Pendred syndrome [10] . This allelic variant displayed a complete lack of function (Fig. 1a) , which indicates that F667C is a pathogenic loss of function mutation.
The allelic variants V88I, V609G and G740S where found with approximately the same frequency in the group of normal-hearing controls belonging to the Spanish population and in the cohort of deaf patients (Table 1 and [37] ); for this reason, it is impossible to unambiguously define their pathogenic potential without performing a functional test. Pendrin V88I was previously characterized by us [37] using the fluorometric method and displayed a significant gain of function; here we confirmed this finding by the use of a radiometric method as an alternative approach (Fig. 1b) . Pendrin V609G was previously identified in compound heterozygosity or in heterozygosity with the WT allele in patients with Pendred syndrome and ns-EVA [15, 16, 50] . The assays in this study (Fig. 1a and b) show that the function of this allelic variant is impaired but not completely annihilated, thereby indicating that pendrin V609G could have a pathogenic potential, especially if associated with other genetic and/or environmental factors. The allelic variant G740S was previously identified in a screening of the pendrin gene in a cohort of patients with the clinical diagnosis of EVA or Mondini dysplasia [51] . The functional studies reported here (Fig. 1a,b and 2b) show that pendrin G740S has a modest, but significant gain of function compared to WT, thereby excluding this allelic variant as a genetic determinant for syndromic or non-syndromic deafness. Interestingly, the gain of function was observed for both the iodide transport (Fig. 1a and b) and Cl -/OH -exchange activity (Fig. 2b) .
In summary, this work shows the functionality of eight (six of which were previously uncharacterized) pendrin allelic variants in which the results of a fluorometric method [41] suitable for measuring the iodide transport of pendrin were validated (Fig. 1c) with a radiometric method [45] . Pendrin P70L, P301L and F667C displayed a loss of function, whereas V609G and D687Y caused a significant reduction of function. Therefore, these allelic variants can be assumed to be pathogenic. The function of pendrin V88I, F354S, G740S was not reduced compared to WT; consequently these allelic variants should not be considered as genetic determinants for Pendred syndrome/ns-EVA. F354S is most likely a benign polymorphism. Surprisingly, pendrin V88I and G740S showed a modest, but significant, gain of function; these isoforms could potentially participate in the pathogenesis of hypertension and/or exacerbations of asthma and COPD [26] .
Conclusion
Functional characterization of pendrin allelic variants is essential for the identification of substitutions whose function is not reduced and, as a consequence, should not be considered as genetic determinants of Pendred syndrome or ns-EVA. Amino acid substitutions involving a proline have a detrimental effect on the function of pendrin. The identification of allelic variants with gain of function is of particular interest. Given the possible role of pendrin in the pathogenesis of hypertension, COPD and asthma, these variants could be genetic modifiers contributing to the severity of the phenotype and/or exacerbations of compromised airway function. 
